Active Ingredient History

  • Now
Radequinil is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABAA receptor. It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.   Wikipedia

  • SMILES: COc1cccc(c1)c2nccc3NC(=O)C(=Cc23)c4noc(C)n4
  • Mol. Mass: 334.34
  • ALogP: 2.96
  • ChEMBL Molecule:
More Chemistry
5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-2-oxo-1,2-dihydro-1,6-naphthyridine | ac3933 | ac 3933 | ac-3933 | ave-3933 | radequinil | resequinil | sx-3933


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue